These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 34755269)

  • 1. Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID).
    Absalón-Aguilar A; Rull-Gabayet M; Pérez-Fragoso A; Mejía-Domínguez NR; Núñez-Álvarez C; Kershenobich-Stalnikowitz D; Sifuentes-Osornio J; Ponce-de-León A; González-Lara F; Martín-Nares E; Montesinos-Ramírez S; Ramírez-Alemón M; Ramírez-Rangel P; Márquez MF; Plata-Corona JC; Juárez-Vega G; Gómez-Martín D; Torres-Ruiz J
    J Gen Intern Med; 2022 Jan; 37(1):4-14. PubMed ID: 34755269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding Colchicine to the Antiretroviral Medication - Lopinavir/Ritonavir (Kaletra) in Hospitalized Patients with Non-Severe Covid-19 Pneumonia: A Structured Summary of a Study Protocol for a Randomized Controlled Trial.
    Dalili N; Kashefizadeh A; Nafar M; Poorrezagholi F; Firouzan A; Samadian F; Samavat S; Ziaie S; Fatemizadeh S
    Trials; 2020 Jun; 21(1):489. PubMed ID: 32503620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.
    Tardif JC; Bouabdallaoui N; L'Allier PL; Gaudet D; Shah B; Pillinger MH; Lopez-Sendon J; da Luz P; Verret L; Audet S; Dupuis J; Denault A; Pelletier M; Tessier PA; Samson S; Fortin D; Tardif JD; Busseuil D; Goulet E; Lacoste C; Dubois A; Joshi AY; Waters DD; Hsue P; Lepor NE; Lesage F; Sainturet N; Roy-Clavel E; Bassevitch Z; Orfanos A; Stamatescu G; Grégoire JC; Busque L; Lavallée C; Hétu PO; Paquette JS; Deftereos SG; Levesque S; Cossette M; Nozza A; Chabot-Blanchet M; Dubé MP; Guertin MC; Boivin G;
    Lancet Respir Med; 2021 Aug; 9(8):924-932. PubMed ID: 34051877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
    Diaz R; Orlandini A; Castellana N; Caccavo A; Corral P; Corral G; Chacón C; Lamelas P; Botto F; Díaz ML; Domínguez JM; Pascual A; Rovito C; Galatte A; Scarafia F; Sued O; Gutierrez O; Jolly SS; Miró JM; Eikelboom J; Loeb M; Maggioni AP; Bhatt DL; Yusuf S;
    JAMA Netw Open; 2021 Dec; 4(12):e2141328. PubMed ID: 34964849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.
    Deftereos SG; Giannopoulos G; Vrachatis DA; Siasos GD; Giotaki SG; Gargalianos P; Metallidis S; Sianos G; Baltagiannis S; Panagopoulos P; Dolianitis K; Randou E; Syrigos K; Kotanidou A; Koulouris NG; Milionis H; Sipsas N; Gogos C; Tsoukalas G; Olympios CD; Tsagalou E; Migdalis I; Gerakari S; Angelidis C; Alexopoulos D; Davlouros P; Hahalis G; Kanonidis I; Katritsis D; Kolettis T; Manolis AS; Michalis L; Naka KK; Pyrgakis VN; Toutouzas KP; Triposkiadis F; Tsioufis K; Vavouranakis E; Martinèz-Dolz L; Reimers B; Stefanini GG; Cleman M; Goudevenos J; Tsiodras S; Tousoulis D; Iliodromitis E; Mehran R; Dangas G; Stefanadis C;
    JAMA Netw Open; 2020 Jun; 3(6):e2013136. PubMed ID: 32579195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colchicine for the treatment of COVID-19.
    Mikolajewska A; Fischer AL; Piechotta V; Mueller A; Metzendorf MI; Becker M; Dorando E; Pacheco RL; Martimbianco ALC; Riera R; Skoetz N; Stegemann M
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD015045. PubMed ID: 34658014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
    Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
    Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colchicine anti-inflammatory therapy for non-intensive care unit hospitalized COVID-19 patients: results from a pilot open-label, randomized controlled clinical trial.
    Haroon MZ; Farooq U; Ashraf S; Zeb S; Gillani SY; Malik S; Ali R; Irshad R; Mehmood Z; Abbas Y; Masood A; Ghafoor A; Khalil AT; Asif H; Khan S; Ujjan ID; Nigar R; Livingstone S; Pascual-Figal DA; Togni S; Allergini P; Riva A; Khan A
    J Physiol Pharmacol; 2022 Jun; 73(3):. PubMed ID: 36302537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
    JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial.
    Rahman M; Datta PK; Islam K; Haque M; Mahmud R; Mallik U; Hasan P; Haque M; Faruq I; Sharif M; Ratul RH; Azad KAK; Miah T; Rahman MM
    PLoS One; 2022; 17(11):e0277790. PubMed ID: 36383611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial.
    Muller M; Lefebvre F; Harlay ML; Glady L; Becker G; Muller C; Aberkane O; Tawk M; Julians M; Romoli A; Hecketsweiler S; Schneider F; Pottecher J; Chamaraux-Tran TN
    Trials; 2021 Feb; 22(1):131. PubMed ID: 33573681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).
    Bonifácio LP; Ramacciotti E; Agati LB; Vilar FC; Silva ACTD; Louzada Júnior P; Fonseca BALD; Souza HCC; Oliveira CCC; Aguiar VCR; Quadros CAA; Dusilek C; Itinose K; Risson R; Ferreira LRR; Lopes RD; Kallas EG; Bellissimo-Rodrigues F
    Rev Soc Bras Med Trop; 2023; 56():e0565. PubMed ID: 37075454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.